Please wait while the formulary information is being retrieved.
SURVANTA (BERACTANT)
- Prevention of respiratory distress in the newborn
- Respiratory distress syndrome in the newborn
25 mg/mL intratracheal suspension
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
SURVANTA (BERACTANT)
- Prevention of respiratory distress in the newborn
- Respiratory distress syndrome in the newborn
- Bradycardia
- None
More Frequent
Severe
Less Severe
- Apnea
- Endotracheal tube blockage
- Hypercapnia
- Hypertension
- Hypotension
- Pallor
- Peripheral vasoconstriction
- Pulmonary hemorrhage
- Sepsis
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Pneumonia
- Seizure disorder
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Beractant
No data available.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | No data available. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Respiratory distress syndrome in the newborn | |
| P22.0 | Respiratory distress syndrome of newborn |
| 0-9 | A-Z |
|---|---|
| P22.0 | Respiratory distress syndrome of newborn |
Formulary Reference Tool